NextCure (NXTC) Cash from Financing Activities (2018 - 2026)
NextCure (NXTC) posted quarterly Cash from Financing Activities of $1.2 million for Q1 2026, down 93.85% quarter-over-quarter from $20.3 million in Q4 2025.
NextCure (NXTC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
NextCure's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $21.6 million (changed N/A YoY), while the FY2025 annual figure was $22.3 million, up 15394.44% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.2 million, down from $20.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $20.3 million in Q4 2025, with the low at $1000.0 in Q1 2024.
- The 5-year median for Cash from Financing Activities is $71000.0 (2023), against an average of $2.4 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities sank 50.41% in 2022, then surged 54745.95% in 2025.
- NextCure's Cash from Financing Activities stood at $61000.0 in 2022, then increased by 16.39% to $71000.0 in 2023, then sank by 47.89% to $37000.0 in 2024, then soared by 54745.95% to $20.3 million in 2025, then slumped by 93.85% to $1.2 million in 2026.
- Business Quant data shows NXTC's Cash from Financing Activities at $1.2 million in Q1 2026, $20.3 million in Q4 2025, and $37000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 22,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22,000.00 |
| Jun 30, 2026 | 22,000.00 |
| Mar 31, 2026 | 1.25 Mn |
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 20.29 Mn |
| Dec 31, 2025 | 20.29 Mn |
| Dec 31, 2024 | 37,000.00 |
| Dec 31, 2024 | 37,000.00 |
| Jun 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 106,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Jun 30, 2022 | 79,000.00 |
| Jun 30, 2022 | 79,000.00 |
| Mar 31, 2022 | 60,000.00 |
| Mar 31, 2022 | 60,000.00 |